Abstract: The present invention relates to a method for prevention and/or treatment of an autoimmune disease, comprising administering a composition, said composition comprising at least one beta cell autoantigen, to a subject The subject may have a serum vitamin-D level above 50 nanomole/liter or the composition may be administered by intralymphatic injection or injection directly into a lymph node, or over a period of weeks, months, or years.

Abstract: The present invention relates to a method for treatment or prevention of an autoimmune disease in a patient, comprising: (a) Determining the HLA genotype of the patient; and (b) Subjecting the patient to a treatment regimen based on said genotype.

Abstract: The present invention relates to the use of at least two autoantigens specific to an autoimmune disease for treatment of said disease. The invention further relates to a method for treatment or prevention of an autoimmune disease, comprising administering to a subject such a pharmaceutical composition or administering to a subject at least two pharmaceutical compositions, each comprising at least one autoantigen which is not present in another such pharmaceutical composition, and which autoantigen is specific to an autoimmune disease.

Abstract: Provided herein, among other things, is a method for prevention and/or treatment of an autoimmune disease. In some embodiments, the method may comprise administering to a subject a composition, said composition comprising at least one ? cell autoantigen, by intralymphatic injection or injection directly into a lymph node.

Abstract: The present invention relates to a method for in vitro cultivation of hematopoietic and/or mesenchymal cells, wherein said cells are cultivated in a cultivation medium comprising gamma-aminobutyric acid (GABA) or a GABA receptor agonist, to cells obtained by such a method and therapeutic use of such cells in methods of treatment of autoimmune, inflammatory or allergic disorder. The invention further relates to pharmaceutical compositions comprising the cells and cultivation media for use in the method according to the invention.

Abstract: The present invention relates to the use of gliadin in medicine, in combination with gamma aminobutyric acid, and/or an antigen such as a beta cell autoantigen.

Abstract: The present invention relates to a method for prevention and/or treatment of an autoimmune disease, comprising administering a composition, said composition comprising at least one beta cell autoantigen, to a subject The subject may have a serum vitamin-D level above 50 nanomole/liter or the composition may be administered by intralymphatic injection or injection directly into a lymph node, or over a period of weeks, months, or years.

Abstract: The present invention regards methods and formulations for the treatment of diabetes and the prevention of autoimmune diabetes. The invention includes the administration of human recombinant GAD65 protein in a pharmaceutically acceptable adjuvant.

Abstract: The present invention relates to methods and formulations for GAD-vaccination to evoke a systemic effect rather that a GAD-specific effect. The present invention may therefore be used in the treatment of disease in humans not bearing on a GAD-specific effect. The invention includes a method to treat an autoimmune disease or disorder by administering at least one sequestered autoantigen in a prime and boost regimen for sensitization purposes followed by a boost for treatment purposes. This may be done upon diagnosis. Examples of sequestered autoantigens include: GAD65, GAD67, Pro-Insulin, Basic Myelin Protein, MOG and Chondrotoin II. The present invention relates to medications and methods for treatment of autoimmune disease within six months from diagnosis.

Abstract: The present invention regards methods and formulations for the treatment of diabetes and the prevention of autoimmune diabetes. The invention includes the administration of human recombinant GAD65 protein in a pharmaceutically acceptable adjuvant.

Abstract: The present invention regards methods and formulations for the treatment of diabetes and the prevention of autoimmune diabetes. The invention includes the administration of human recombinant GAD65 protein in a pharmaceutically acceptable adjuvant.

Abstract: The present invention regards methods and formulations for diagnosis, prevention and treatment of disease. More particularly, the present invention teaches methods and formulations for diagnosis, prevention and treatment with antigen in autoimmune disease, allergy, rejection of transplants and cancer. Examples illustrate how the methods and formulations of the invention may be used for diagnosis and amelioration of autoimmune diabetes in which the 65 kd isotype of glutamic acid decarboxylase (GAD) is a major antigen.

Abstract: The present invention regards methods and formulations for the treatment of diabetes and the prevention of autoimmune diabetes. The invention includes the administration of human recombinant GAD65 protein in a pharmaceutically acceptable adjuvant.

Abstract: The present invention regards methods and formulations for the treatment of diabetes and the prevention of autoimmune diabetes. The invention includes the administration of human recombinant GAD65 protein in a pharmaceutically acceptable adjuvant.

Abstract: The present invention regards methods and formulations for diagnosis, prevention and treatment of disease. More particularly, the present invention teaches methods and formulations for diagnosis, prevention and treatment with antigen in autoimmune disease, allergy, rejection of transplants and cancer. Examples illustrate how the methods and formulations of the invention may be used for diagnosis and amelioration of autoimmune diabetes in which the 65 kd isotype of glutamic acid decarboxylase (GAD) is a major antigen.

Abstract: The present invention regards methods and formulations for diagnosis, prevention and treatment of disease. More particularly, the present invention teaches methods and formulations for diagnosis, prevention and treatment with antigen in autoimmune disease, allergy, rejection of transplants and cancer. Examples illustrate how the methods and formulations of the invention may be used for diagnosis and amelioration of autoimmune diabetes in which the 65kd isotype of glutamic acid decarboxylase (GAD) is a major antigen.

Abstract: A system and a method for evaluation of gastrointestinal function is presented. The system consists of a catheter, a recorder and software. The catheter includes one or more CdTe sensors for measuring isotope activity. The catheter CdTe sensors are placed in the gastrointestinal tract to measure gastric emptying or gastrointestinal output after administration of radiolabeled liquid or solid meals. Data is stored in the recorder or displayed on-line on a computer screen. Other parameters such as pH can be added for a more complete evaluation of gastrointestinal function. The computer software is written for the Windows environment. The software includes provisions for general ambulatory and stationary data acquisition. The software also includes realtime analysis combined with an extensive patient journal where all items are described as objects in understandable userfriendly language connected to a database.

Abstract: A modified GAD especially characterized by a substantially preserved immunogenicity in connection with diabetes compared with a non-modified GAD and a reduced or non-existent effectivity in connection with a GABA-synthesis. The invention relates also to a method for manufacturing a modified GAD, a method for supplying a modified GAD, nucleotide sequence encoding the modified GAD, a vector containing the nucleic acid sequence, a host, a pharmaceutical composition comprising modified GAD and use thereof for treating and/or preventing autoimmune disorders such as IDDM.

Abstract: A method and system for determining the presence of one or more components in a liquid substance including illumination of the substance utilizing a light with at least one definite wave length preferably within the almost infrared area and detecting transmitted and/or reflected light and analyzing the detected light wherein the detection is performed extremely fast so as to detect a step response corresponding to an approaching or fading light pulse transmitted or reflected through the substance.

Abstract: A method and system for the determination of the pH of a fluid by measuring the pH of the fluid and thereafter correcting the pH based upon the determination of measured and/or adjusted values of at least one other parameter, such as PO.sub.2 and PCO.sub.2, which relate to the fluid.